JP2017222654A5 - - Google Patents

Download PDF

Info

Publication number
JP2017222654A5
JP2017222654A5 JP2017115935A JP2017115935A JP2017222654A5 JP 2017222654 A5 JP2017222654 A5 JP 2017222654A5 JP 2017115935 A JP2017115935 A JP 2017115935A JP 2017115935 A JP2017115935 A JP 2017115935A JP 2017222654 A5 JP2017222654 A5 JP 2017222654A5
Authority
JP
Japan
Prior art keywords
antibody
association
arginine
arginine amide
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017115935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017222654A (ja
JP6469765B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017222654A publication Critical patent/JP2017222654A/ja
Publication of JP2017222654A5 publication Critical patent/JP2017222654A5/ja
Application granted granted Critical
Publication of JP6469765B2 publication Critical patent/JP6469765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017115935A 2011-07-19 2017-06-13 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 Active JP6469765B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011157654 2011-07-19
JP2011157654 2011-07-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013524738A Division JP6176849B2 (ja) 2011-07-19 2012-07-19 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Publications (3)

Publication Number Publication Date
JP2017222654A JP2017222654A (ja) 2017-12-21
JP2017222654A5 true JP2017222654A5 (enExample) 2018-02-15
JP6469765B2 JP6469765B2 (ja) 2019-02-13

Family

ID=47558197

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013524738A Active JP6176849B2 (ja) 2011-07-19 2012-07-19 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
JP2017115935A Active JP6469765B2 (ja) 2011-07-19 2017-06-13 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013524738A Active JP6176849B2 (ja) 2011-07-19 2012-07-19 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Country Status (4)

Country Link
US (2) US9574005B2 (enExample)
EP (1) EP2735315B1 (enExample)
JP (2) JP6176849B2 (enExample)
WO (1) WO2013012022A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JP2017502922A (ja) * 2013-10-29 2017-01-26 アルブミディクス アクティーゼルスカブ 抗体組成物
EP4671270A3 (en) * 2013-12-27 2026-03-18 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
WO2017057644A1 (ja) * 2015-09-30 2017-04-06 持田製薬株式会社 高濃度抗体含有液体製剤
KR102456731B1 (ko) 2016-03-03 2022-10-24 리제너론 파아마슈티컬스, 인크. Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗rsv抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
EP3763356A1 (en) * 2019-07-12 2021-01-13 Ludwig-Maximilians-Universität München Excipient for biotherapeutics
EP4062933A4 (en) * 2019-11-20 2023-12-13 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
JP2025078889A (ja) * 2022-02-03 2025-05-21 天野エンザイム株式会社 酵素製剤
WO2025186423A1 (en) 2024-03-07 2025-09-12 Csl Behring Ag Immunoglobulin composition and method of generating an aerosol

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst B型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
JP2942412B2 (ja) 1991-12-26 1999-08-30 鐘紡株式会社 化粧料
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル ジェネシス,インク. 異種抗体の生産
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
TWI241345B (en) 2000-03-10 2005-10-11 Chugai Pharmaceutical Co Ltd Apoptosis inducing polypeptide
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
WO2002033072A1 (fr) 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps degrade, agoniste de tpo
EP1391209A4 (en) 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
JP4083634B2 (ja) 2002-07-11 2008-04-30 旭化成ファーマ株式会社 光に安定なカルシトニン水溶液
JP3976257B2 (ja) 2002-09-17 2007-09-12 栄研化学株式会社 蛋白質の安定化方法
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
JP2007332093A (ja) 2006-06-16 2007-12-27 Apro Life Science Institute Inc タンパク質のリフォールディング添加剤及びそれを用いたタンパク質の再生方法
EP2114451A2 (en) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
JP5119545B2 (ja) 2007-06-19 2013-01-16 国立大学法人 筑波大学 蛋白質を含む液状組成物中における蛋白質の安定化方法
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009104369A1 (ja) 2008-02-22 2009-08-27 パナソニック株式会社 血漿に含まれる成分の検出方法ならびにそれに用いられる試薬および検出デバイス
TWI505838B (zh) * 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
RU2012151500A (ru) * 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤

Similar Documents

Publication Publication Date Title
JP2017222654A5 (enExample)
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
BR112017008660A2 (pt) formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf
CY1124592T1 (el) Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες
AR111455A1 (es) Formulación estable de anticuerpo
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
EA201790997A1 (ru) Композиции гликопептидов
CO2020013552A2 (es) Formulación de anticuerpos
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
CR20190400A (es) Formulaciones de anticuerpo monoclonal anti-vrs
UA122478C2 (uk) Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1
JOP20200140A1 (ar) صيغ لتركيبات لقاح فيروس حُمى الضنك
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
PY1128718A (es) Formulaciones estabilizadas que contienen anticuerpos anti- ngf
BRPI0514340A (pt) formulações de estabilização
EA201890771A1 (ru) Соли и твердые формы монобактамного антибиотика
JP2019501920A5 (enExample)
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
AR093297A1 (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EA202091003A1 (ru) Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3
EA202192568A1 (ru) Стабилизированные составы, содержащие антитела к il-33
MX2021007393A (es) Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico